Controlled‐release mesalamine (1 ‐ 2 g/day) vs placebo
Induction of remission (CDAI <=150 + decrease of >=50 or as defined by Tvede et al) · patients with Induction of remission or response in Crohn's disease
Controlled‐release mesalamine (1 ‐ 2 g/day) showed no clear difference in induction of remission (CDAI <=150 + decrease of >=50 or as defined… compared with placebo (low certainty).
1 finding from 1 review
- Aminosalicylates for induction of remission or response in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.46 [0.89, 2.4]2 studies · 302 participantsLow